Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy
Retrognathism, Prognathism, Orthognathic Surgery
About this trial
This is an interventional treatment trial for Retrognathism focused on measuring Bilateral Sagittal Split Osteotomy, Neurosensory Disturbances
Eligibility Criteria
Inclusion Criteria: Patients with dentomaxillofacial anomalies who present a complete mandibular dental arch and who have not undergone previous mandibular surgery.
Exclusion Criteria:
patients who:
- do not have sufficient information in their clinical records
- cannot be contacted
- do not attend their check-ups (for at least 24 postoperative months in cases with DNS)
- have refused consent to the use of their information for purposes of research.
- already undergoing Orthognathic Surgery
- with systemic conditions prone to alter recovery patterns or serious systemic diseases (decompensated metabolic disorders; neoplasms; osteodysplasias; neuropathies).
- pregnancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
Citoneurone
Melatonin
Hydroxycobalamin
Placebo
Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneurone). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive peripheral neural disorders.
Group B will receive the pharmacology treatment with 10 mg Melatonin. One capsule orally at night for 60 days.
Group C will receive the pharmacology treatment with 1 mg hydroxycobalamin (vitamin B12). One capsule daily for 60 days.
The controls will receive 1 capsule placebo containing 5 mg starch to be taken once daily.